DCF Valuation
Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) DCF Valuation — Is SHPMY undervalued?
The estimated DCF fair value of one Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) share is $213.83. Compared to the current market price of $7.04, the stock is undervalued by 2937.4%.
DCF fair value
$213.83
Market price
$7.04
Upside / downside
+2937.4%
Prefer the inverse question? See what growth rate the market is pricing into SHPMY →
Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) DCF valuation FAQ
What is the DCF fair value of Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY)?
The discounted-cash-flow model estimates the intrinsic fair value of one Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) share at $213.83, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) overvalued or undervalued?
Against the current market price of $7.04, the DCF fair value of $213.83 implies SHPMY is undervalued by 2937.4%.
How is the SHPMY DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Shanghai Pharmaceuticals Holding Co Ltd ADR's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Shanghai Pharmaceuticals Holding Co Ltd ADR files a new quarterly or annual report.
How this SHPMY valuation is built
The model projects ten years of Shanghai Pharmaceuticals Holding Co Ltd ADR's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Shanghai Pharmaceuticals Holding Co Ltd ADR's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Shanghai Pharmaceuticals Holding Co Ltd ADR files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.